fda glp-1 compounding enforcement november 2025 Covering Drugs: Employers' Top Questions Answered – Sequoia FDA Drug Recalls and Warnings:

The transition period is not the time for major dietary changes, as it introduces too many variables to evaluate how well the new medication is working

Similar content being viewed by others Introduction Obesity is a major chronic disease that continues to increase in prevalence worldwide and constitutes a key risk factor for development and progression of numerous related diseases including hypertension, dyslipidaemia and type 2 diabetes 1

doi: 10.1007/978-3-031-58572-2_9 480 HarperAVijayakumarVOuwehandACTer HaarJObisDEspadalerJet al

In the US, semaglutide is marketed as a diabetes medicine under the familiar brand name Ozempic